Evaluation of drug-drug interactions with fesoterodine

European Journal of Clinical Pharmacology

Volumn 65, Issue 6, 2009, Pages 551-560

  Malhotra, Bimal ^a   Sachse, Richard ^b   Wood, Nolan ^c  

^a PFIZER INC   (United States)

^b Schwarz Pharma AG   (Germany)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Drug drug interactions; Fesoterodine; Ketoconazole; Overactive bladder; Rifampicin

Indexed keywords

ANTIFUNGAL AGENT; BENZHYDRYL DERIVATIVE; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A; FESOTERODINE; KETOCONAZOLE; MUSCARINIC RECEPTOR BLOCKING AGENT; PLACEBO;

AREA UNDER THE CURVE; ARTICLE; DRUG ANTAGONISM; DRUG INTERACTION; DRUG SCREENING; HUMAN;

ANTIFUNGAL AGENTS; AREA UNDER CURVE; BENZHYDRYL COMPOUNDS; CYTOCHROME P-450 CYP3A; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; HUMANS; KETOCONAZOLE; MUSCARINIC ANTAGONISTS; PLACEBOS;

EID: 68849110762     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-009-0648-1     Document Type: Article

References (21)

1. Abrams P, Artibani W, Cardozo L et al (2006) Reviewing the ICS 2002 terminology report: The ongoing debate. Neurourol Urodynam 25:293
2. Abrams P, Cardozo L, Fall M et al (2003) The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 61(1):37-49 (Pubitemid 36151708)
3. Wein AJ, Rackley RR (2006) Overactive bladder: a better understanding of pathophysiology, diagnosis and management. J Urol 175(3 Pt 2):S5-S10 (Pubitemid 43177185)
4. Stewart WF, Van Rooyen JB, Cundiff GWet al (2003) Prevalence and burden of overactive bladder in the United States. World J Urol 20(6):327-336 (Pubitemid 44175300)
5. Irwin DE, Milsom I, Hunskaar S et al (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50(6):1306-1315 (Pubitemid 44692945)
6. Andersson K-E (2004) Antimuscarinics for the treatment of overactive bladder. Lancet Neurol 3(1):46-53
7. Michel MC (2008) Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. Expert Opin Pharmacother 9(10):1787-1796
8. Malhotra BK, Guan Z, Wood N et al (2008) Pharmacokinetic profile of fesoterodine. Int J Clin Pharmacol Ther 46(11):556-563
9. Nilvebrant L (2001) Clinical experiences with tolterodine. Life Sci 68(22-23):2549-2556
10. Cole P (2004) Fesoterodine, an advanced antimuscarinic for the treatment of overactive bladder: a safety update. Drugs Future 29 (7):715-720
11. Xie HG, Kim RB, Wood AJ et al (2001) Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 41:815-850 (Pubitemid 32385908)
12. Toviaz (fesoterodine fumarate) (2007) Full prescribing information. Pfizer, New York
13. Davis PJ, Stiller RL, Wilson AS et al (2002) In vitro remifentanil metabolism: the effects of whole blood constituents and plasma butyrylcholinesterase. Anesth Analg 95(5):1305-1307 (table of contents) (Pubitemid 35239130)
14. Rosow CE (1999) An overview of remifentanil. Anesth Analg 89 [4 Suppl]:S1-S3
15. Beers R, Camporesi E (2004) Remifentanil update: clinical science and utility. CNS Drugs 18(15):1085-1104 (Pubitemid 40007492)
16. Charasson V, Bellott R, Meynard D et al (2004) Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN-38. Clin Pharmacol Ther 76(6):528-535 (Pubitemid 39601543)
17. Fauci AS, Braunwald E, Kasper DL et al (2008) Harrison's principles of internal medicine, 17th edn. McGraw-Hill, New York
18. Brynne N, Forslund C, Hallen B et al (1999) Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity. Br J Clin Pharmacol 48(4):564-572 (Pubitemid 29454237)
19. Oesch F, Arand M, Benedetti MS et al (1996) Inducing properties of rifampicin and rifabutin for selected enzyme activities of the cytochrome P-450 and UDP-glucuronosyltransferase superfamilies in female rat liver. J Antimicrob Chemother 37(6):1111-1119 (Pubitemid 26258057)
20. Kasper DL, Braunwald E, Hauser S et al (2004) Harrison's principles of internal medicine, 16th edn. McGraw-Hill, New York
21. Olsson B, Landgren BM (2001) The effect of tolterodine on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Clin Ther 23(11):1876-1888 (Pubitemid 33121975)